Designed With Both Patients and the Physicians Who Treat Them in Mind

Integrated components make the procedure, treatment, and ongoing management convenient.



Revi Implant

- Advanced technology allows the device to be miniature in size without the need for revision surgeries due to battery depletion, lead fracture, or lead migration.
- Only 3 cm in length and 3 mm in diameter, this tibial implant delivers reliable and long-lasting performance in a compact form.
- MR Conditional



Revi Wearable

- Innovative lightweight external wearable technology powers the implant, enabling programming changes without regard for energy consumption.
- It is worn around the ankle for ~30 minutes per therapy session based on symptoms, delivering therapy at the patient's convenience.



Revi Clinician Programmer

- Allows for customization of therapy based on a patient's response.
- Enables adjustment of frequency, pulse width, polarity, and amplitude.



Hub

- Wirelessly retrieves therapy data from the Wearable.
- Provides the clinical care team visibility into device usage and status to better support and optimize patient therapy.

Learn About Our Comprehensive Services For:



Patient Support Program



Clinician Training

Indications for Use
The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.

Visit www.bluewindmedical.com for more details.

Caution:
Federal Law restricts these devices to sale by or on the order of a physician. Refer to product instruction manual/package insert for instructions, warnings, precautions, and contraindications. For more information, please contact BlueWind Medical at 888-715-2080, and/or consult BlueWind Medical's website at **www.bluewindmedical.com**.

BlueWind MEDICAL

MKL-0036 Rev. 06 October 2026

Unlock a Path Forward for Your Patients with Urge Urinary Incontinence

Revi®

could be the key to relief for patients looking for a new solution.



BlueWind MEDICAL

Demonstrated Efficacy & Safety



The OASIS Pivotal Trial

A prospective, single-arm, open-label study with 151 patients at 23 medical centers globally was conducted to evaluate the safety and efficacy of the Revi® System for treating patients with Urge Urinary Incontinence (UUI).

Safety

During the pivotal OASIS trial Completers analysis†, Revi demonstrated a favorable safety profile at 36 months.

0% device- or procedure-related serious adverse events

0% adverse events related to surgical revision or reintervention*

ALL device- and procedure-related AEs were either mild or moderate

Outcomes at 36 Months

in the Completers analysis† (N=90) include[1]:

79% of patients had **≥50% reduction** in UUI episodes[1]

63% of patients had **≥ 75% reduction** in UUI episodes[1]

28% dry rate on a 3 day bladder diary[1]

77% completed **≥1 treatment per day** [1]

The Power of Proof

In the OASIS Study Completers analysis† at 36 months:

95% patient satisfaction at 36 months (83/87)[1]

82% PGI-I score of very much or much better (74/90)[1]

How it Works

Proven Process. Single Procedure.

Revi is a patient-centric therapy with a unique implant placement and system design. It provides an alternative treatment solution that may be better suited to some of your UUI patients.

Minimally Invasive: The miniature device is implanted in the ankle region near the posterior tibial nerve in a single predictable procedure under local anesthesia.

Predictable Placement: Subfascial placement allows for direct visualization of the posterior tibial nerve. Intraoperative testing and suture fixation allow for predictable control.

Customized Therapy: Optimized treatment based on patient response. Clinician Programmer and Hub allow clinical care team visibility into device usage and status to better support and optimize patient therapy.

Convenient Therapy.

Revi is designed to be easy to use at home so it can fit into patients' lives and help them stay compliant with therapy.

Lightweight Wearable: Wireless battery operated Wearable is worn around the ankle to activate the implant, only during therapy.

Convenient Sessions: At the patient's convenience for about 30 minutes once daily, based on symptoms.

Customized Programming: With 4 preset treatment programs set for use at home.

Reference:

1. Amundsen C. et al. Three-year efficacy and safety of Revi Implantable Tibial Neuromodulation from the pivotal OASIS Study. April 2026 JUro https://doi.org/10.1097/JU.0000000000005062

* Due to battery depletion, implant migration, or lead fracture.

† Completers analysis represents the patients with available data at 36 months. Satisfaction results are from 87 patients.